Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases (HDACs).1 Unlike the HDAC inhibitor suberoylanilide hydroamic acid, which has a fast-on/fast-off HDAC binding rate, pimelic diphenylamide 106 progressively binds HDACs and remains bound after wash-out. As a result, the IC50 of pimelic diphenylamide 106 decreases over time. With prolonged preincubation (1-3 hours), pimelic diphenylamide inhibits the class I HDACs (IC50 = 150, 760, 370, and 5,000 nM for HDAC1, 2, 3, and 8, respectively) but not the class II HDACs (IC50 > 180 μM for HDAC4, 5, and 7).1 Pimelic diphenylamide 106 and related benzamide HDAC inhibitors may have therapeutic value in Friedrich’s ataxia1,2,3 and Huntington’s disease,4 in part due to their low animal toxicity.
1
Chou, C.J., Herman, D., and Gottesfeld, J.M. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J Biol Chem283(51)35402-35409(2008).
2
Rai, M., Soragni, E., Jenssen, K., et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS One3(4)(2008).
3
Herman, D., Jenssen, K., Burnett, R., et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich’s ataxia. Nat Chem Biol2(10)551-558(2006).
4
Thomas, E.A., Coppola, G., Desplats, P.A., et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington’s disease transgenic mice. Proc Natl Acad Sci USA105(40)15564-15569(2008).
Room temperature
in continental US; may vary elsewhere
SMILES
Copy SMILES to clipboard
O=C(CCCCCC(=O)Nc1ccccc1N)Nc1ccc(C)cc1
Background Reading
Thomas, E.A., Coppola, G., Desplats, P.A., et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington’s disease transgenic mice. Proc Natl Acad Sci USA105(40)15564-15569(2008).
Chou, C.J., Herman, D., and Gottesfeld, J.M. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J Biol Chem283(51)35402-35409(2008).
Rai, M., Soragni, E., Jenssen, K., et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS One3(4)(2008).
Herman, D., Jenssen, K., Burnett, R., et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich’s ataxia. Nat Chem Biol2(10)551-558(2006).